Product Information Sheet for NR-2642

Anthrax Vaccine Adsorbed (AVA) (BioThrax™)

Catalog No. NR-2642

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

U.S. Department of Defense Joint Vaccine Acquisition Program

Manufacturer:

Emergent BioSolutions™

Product Description:

Anthrax Vaccine Adsorbed (AVA) (BioThrax™) was produced from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of *Bacillus anthracis*. The final product was prepared from the sterile filtrate culture fluid and contains proteins, including the 83kDa protective antigen protein, released during the growth period. AVA (BioThrax™) does not contain any dead or live bacteria. The expiration date for the clinical product was August 18, 2005. NR-2642 is being made available for research use only.

Material Provided:

Each vial contains approximately 5 mL of sterile AVA (BioThrax™) in 1.2 mg/mL aluminum (added as aluminum hydroxide) in 0.85% sodium chloride. Benzethonium chloride (25 µg/mL) and formaldehyde (100 µg/mL) have been added as preservatives.

Packaging/ Storage:

NR-2642 was packaged aseptically, in rubber-stoppered glass vials. The product is shipped at 4°C on refrigerated bricks and should be stored at 2–8°C on arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Anthrax Vaccine Adsorbed (AVA) (BioThrax™), NR-2642."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Splino, M., et al. "Anthrax Vaccines." Ann. Saudi Med. 25 (2005): 143–149. PubMed: 15977694.
2. Little, S. F., et al. "Effect of Aluminum Hydroxide Adjuvant and Formaldehyde in the Formulation of rPA Anthrax Vaccine." Vaccine 25 (2007): 2771–2777. PubMed: 17240008.
3. Pittman, P. R., et al. "Patterns of Antibody Response in Humans to the Anthrax Vaccine Adsorbed (AVA) Primary (Six-Dose) Series." Vaccine 24 (2006): 3654–3660. PubMed: 16497418.

ATCC® is a trademark of the American Type Culture Collection.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org